Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K C Liu

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
BMC Cancer|May 16, 2021
Capecitabine and stereotactic radiation in the management of breast cancer brain metastasesMatthew N Mills, Afrin Naz, Chetna Thawani, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitorsKevin K-C Liu, Shubha Bagrodia, Simon Bailey, et al.
Chemical Research in Toxicology|May 29, 2010
Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosisAmit S Kalgutkar, David A Griffith, Tim Ryder, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Gut Microbiome (Cambridge, England)|June 22, 2026
Associations between gut microbiome and 24-hour blood pressure variability: a cross-sectional study highlighting sex differences and potential therapeutic targetsPreeti Dinesh Virwani, Gordon Qian, Carman Nga-Man Cheung, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonistsMary T Didiuk, David A Griffith, John W Benbow, et al.
Science Translational Medicine|July 2, 2025
A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasisShawn C Chafe, Kui Zhai, Nikoo Aghaei, et al.
Science Translational Medicine|November 16, 2022
A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelaePeter M George, Anna Reed, Sujal R Desai, et al.
Hypertension (Dallas, Tex. : 1979)|April 19, 2023
Sex Differences in Association Between Gut Microbiome and Essential Hypertension Based on Ambulatory Blood Pressure MonitoringPreeti Dinesh Virwani, Gordon Qian, Matthew S S Hsu, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
BMC Cancer|May 16, 2021
Capecitabine and stereotactic radiation in the management of breast cancer brain metastasesMatthew N Mills, Afrin Naz, Chetna Thawani, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitorsKevin K-C Liu, Shubha Bagrodia, Simon Bailey, et al.
Chemical Research in Toxicology|May 29, 2010
Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosisAmit S Kalgutkar, David A Griffith, Tim Ryder, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Gut Microbiome (Cambridge, England)|June 22, 2026
Associations between gut microbiome and 24-hour blood pressure variability: a cross-sectional study highlighting sex differences and potential therapeutic targetsPreeti Dinesh Virwani, Gordon Qian, Carman Nga-Man Cheung, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonistsMary T Didiuk, David A Griffith, John W Benbow, et al.
Science Translational Medicine|July 2, 2025
A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasisShawn C Chafe, Kui Zhai, Nikoo Aghaei, et al.
Science Translational Medicine|November 16, 2022
A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelaePeter M George, Anna Reed, Sujal R Desai, et al.
Hypertension (Dallas, Tex. : 1979)|April 19, 2023
Sex Differences in Association Between Gut Microbiome and Essential Hypertension Based on Ambulatory Blood Pressure MonitoringPreeti Dinesh Virwani, Gordon Qian, Matthew S S Hsu, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 14